Follow The Filings

SGRY Surgery Partners Inc.

Health Care, filed as SURGERY PARTNERS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 2

  • 3 Owners
  • Max 53.7%
  • $172M
  • 1 new 1 reduce 1 exit

In 2026 Q2 Howard Marks opened a position in Surgery Partners, King Street Capital Management trimmed, and Glenview Capital Management sold out.

Who owns this now

Largest portfolio weights among holders, up to 53.7% (King Street Capital Management). Not free-float ownership.

  1. King Street Capital Management Reduce 53.7%
  2. Davidson Kempner Capital Mana... 0.67%
  3. Howard Marks New 0.20%

Who owns SGRY

Sorted by value, long equity only, as of 2026 Q2.

History
King Street Capital Management 53.7% Reduce −40.8% 6,058,141 $102M History
Davidson Kempner Capital Management 0.67% Hold 3,336,464 $56M History
Howard Marks, Oaktree Capital Management 0.20% New 0.20% 862,588 $14M History
Glenview Capital Management exited 2026 Q2 Last 2026 Q1 0.54% Exit −0.54% 1,800,000 $21M History

3 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by SGRY's executives, directors and 10% owners in the last 12 months, from their Form 4s

All SGRY insider trades
  • $161K bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Teresa DeLuca Director
    Buy
    $161K 11,250 shares at $14.33 +20% to stake
    Traded Aug 18 Filed Aug 20
    ↗

Also filed in the last 12 months, not counted as buying or selling: 26 stock grants and 12 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
DEFA14A Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2.74B $3.11B $3.31B
Net income -$11.9M -$168.1M -$77.9M
Net margin * -0.4% -5.4% -2.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.895B $1.12B $1.15B
Total non-current assets * $5.98B $6.77B $6.97B
Total assets $6.88B $7.89B $8.12B
Total current liabilities $523M $624.4M $615.5M
Total equity $1.99B $1.79B $1.71B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $293.8M $300.1M $274.3M
Cash from investing -$225.6M -$488.5M -$246.6M
Cash from financing -$155.2M $262M -$57.3M
Net change in cash -$87M $73.6M -$29.6M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.